Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation : a substudy of a randomized phase III trial.
(2012) Therapeutic Drug Monitoring — Vol. 34, n° 2, p. 143-147 (2012)
Files
Wlodarczyk-2012-Tacrolimuspharmacokinetics.pdf
Restricted Access - Adobe PDF
- 263.58 KB
Details
- Authors
- Abstract
- Tacrolimus is a well-established immunosuppressive agent for the treatment and prevention of solid organ graft rejection. It is available as an immediate-release, twice-daily formulation (Tacrolimus BID) and a prolonged-release, once-daily formulation (Tacrolimus QD). In a previous study of the pharmacokinetics (PK) of these formulations, mean systemic exposure [area under the curve from 0 to 24 hours (AUC0-24)] of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than for Tacrolimus BID; by day 14, systemic exposure was similar; however, the mean dose of Tacrolimus QD was higher to achieve similar systemic exposure as Tacrolimus BID.
- Affiliations
Citations
Wlodarczyk, Z., Ostrowski, M., Mourad, M., Krämer, B. K., Abramowicz, D., Oppenheimer, F., Miller, D., Dickinson, J., & Undre, N. (2012). Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation : a substudy of a randomized phase III trial. Therapeutic Drug Monitoring, 34(2), 143-147. https://doi.org/10.1097/FTD.0b013e31824d1620 (Original work published 2012)